MedTrace Logo

Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer

NCT07041437 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2025-06-27

No results posted yet for this study

Summary

Our study is aimed to evaluate the efficacy and safety of SHR-A2102 combined other antitumor treatments in advanced breast cancer.

Conditions

Interventions

DRUG

SHR-A2102

ADC

DRUG

Adebrelimab

PD-L1 inhibitor

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Hongxia Wang, Chief physician · Fudan University

  • Xichun Hu, Chief physician · Fudan University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-30
Primary Completion
2026-09-30
Completion
2027-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07041437 on ClinicalTrials.gov